Methylphenidate and pharmacological cognitive enhancement: Social representations of university students;Metilfenidato e aprimoramento cognitivo farmacológico: Representações sociais de universitários1

Saude e Sociedade

Volumn 20, Issue 2, 2011, Pages 350-362

  Barros, Denise ^a   Ortega, Francisco ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Biomedical enhancement; Cognition; Focus groups; Methylphenidate; Science; Subjectivity; Technology and society

Indexed keywords

EID: 79960356045     PISSN: 01041290     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-12902011000200008     Document Type: Article

References (43)

1. BUSH, S. Neurocognitive enhancement: ethical considerations for an emerging subspecialty. Applied Neuropsychology, London, v. 13, n. 2, p. 125-136, 2006.
2. BUTCHER, J. Cognitive enhancement raises ethical concerns. Lancet, New York, v. 362, n. 9378, p. 132-133, 2003.
3. CAPLAN, A. Is better best? Scientific American, New York, v. 289, n. 3, p. 104-105, 2003.
4. CAPLAN, A.; ELLIOTT, C. Is it ethical to use enhancement technologies to make us better than well? PLoS Med, San Francisco, v. 3, n. 1, p. 52, 2004.
5. CARLINI-COTRIM, B. Potencialidades da técnica qualitativa grupo focal em investigações sobre abuso de substâncias. Revista de Saúde Pública, São Paulo, v. 30, n. 3, p. 285-293, 1996.
6. CHATTERJEE, A. Cosmetic neurology: the controversy over enhancing movement, mentation, and mood. Neurology, St. Paul, v. 63, n. 6, p. 968-974, 2004.
7. CHAU, V. Popping pills to study: neuroethics in education. Stanford Journal of Neuroscience, Stanford, v. 1, n. 1, p. 18-20, 2007.
8. DEES, R. Slippery slopes, wonder drugs, and cosmetic neurology. Neurology, St. Paul, v. 63, p. 951-952, 2004.
9. DILLER, L. The run on Ritalin: attention deficit disorder and stimulant treatment in the 1990s. The Hastings Center Report, New York, v. 26, n. 2, p. 12-18, 1996.
10. EHRENBERG, A. Le culte de la performance. Paris: Hachette Littératures, 1991.
11. ELLIOTT, C. American bioscience meets the American dream. The American Prospect, Washington, DC, v. 14, p. 38-42, 2003.
12. ELLIOTT, R. et al. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology, Heidelberg, v. 131, n. 2, p. 196-206, 1997.
13. FARAH, M. J. et al. Neurocognitive enhancement: what can we do and what should we do? Nature Reviews Neuroscience, London, v. 5, p. 421-425, 2004.
14. FENTON, A. Buddhism and neuroethics: the ethics of pharmaceutical cognitive enhancement. Developing World Bioethics, Kingston, v. 9, n. 2, p. 47-97, 2009.
15. GREELY, H. et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, London, v. 456, p. 702-705, 2008.
16. GONDIM, S. M. G. Perfil profissional e mercado de trabalho: relação com a formação acadêmica pela perspectiva de estudantes universitários. Estudos de Psicologia, Natal, v. 7, n. 2, p. 299-309, 2002.
17. HALL, K. et al. Illicit use of prescribed stimulant medication among college students. Journal of American College Health, Linthicum, v. 53, n. 4, p. 167-174, 2005.
18. HALL, W. Feeling 'better than well': can our experiences with psychoactive drugs help us to meet the challenges of novel neuroenhancement methods? EMBO Reports, Heidelberg, v. 5, n. 12, p. 1105-1109, 2004.
19. HYMAN, S. Improving our brains? Biosocieties, Cambridge, v. 1, n. 1, p. 103-111, 2006.
20. KASS, L. Beyond therapy: biotechnology and the pursuit of happiness. New York: Harper Collins; 2003.
21. KRUEGER, R. A. Focus groups: a practical guide for applied research. Newbury Park: Sage, 1988.
22. LOW, K. G.; GENDASZEK, A. E. Illicit use of psychostimulants among college students: a preliminary study. Psychology, Health and Medicine, Oxfordshire, v. 7, n. 3, p. 283-287, 2002.
23. MAGUIRE JR, G. Q.; MCGEE, E. M. Implantable brain chips?: time for debate. Hastings Center Report, New York, v. 29, n. 1, p. 7-13, 1999.
24. MAHER, B. Poll results: look who's dopping. Nature, London, v. 452, p. 674-675, 2008.
25. MAURON, A. Renovating the house of being: genomes, souls, and selves. Annals of the New York Academy of Sciences, New York, v. 1001, n. 1, p. 240-251, 2003.
26. MEHTA, M. A. et al. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. The Journal of Neuroscience, Washington, DC, v. 20, n. 6, p. 1-6, 2002.
27. MINAYO, M. C. O desafio do conhecimento: pesquisa qualitativa em saúde. Rio de Janeiro: Abrasco, 1992.
28. MORGAN, D. Focus groups as qualitative research. London: Sage, 1997.
29. NIDA - NATIONAL INSTITUTE ON DRUG ABUSE. Prescription drugs: abuse and addiction. Bethesda, 2005. (Research Report Series)
30. NOVARTIS BIOCIÊNCIAS SA. Ritalina: cloridrato de metilfenidato. Brasília, DF: Anvisa, 2007. Bula. Disponível em: http://www4.anvisa.gov.br/base/visadoc/BM/BM%5B26162-1-0%5D.PDF. Acessoem: 12 maio 2011.
31. RACINE, E.; FORLINI, C. Cognitive enhancement, lifestyle choice or misuse of prescription drugs: ethics blind spots in current debates. Neuroethics, Dordrecht, v. 3, n. 1, p. 1-4, 2008.
32. SAHAKIAN, B.; MOREIN-ZAMIR, S. Professor's little helper. Nature, London, v. 450, n. 20, p. 1157-1159, 2007.
33. SENTENTIA, W. Neuroethical considerations: cognitive liberty and converging technologies for improving human cognition. Annals of the New York Academy of Sciences. New York, v. 1013, p. 221-228, 2004.
34. SINGH, I.; ROSE, N. Neuro-forum: an introduction. Biosocieties, Cambridge, v. 1, n. 1, p. 97-102, 2006.
35. SOLANTO, M. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behavioural Brain Research, Dusseldorf, v. 94, p. 127-152. 1998.
36. SZOBOT, C. M. et al. Neuroimagem no transtorno de déficit de atenção/hiperatividade. Revista Brasileira de Psiquiatria, São Paulo, v. 23, n. 1, p. 32-35, 2001.
37. TETER, C. et al. Prevalence and motives for illicit use of prescription stimulants in an under. The Journal of American College Health, Linthicum, v. 53, n. 6, p. 253-262, 2005.
38. TETER, C. et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy, Boston, v. 26, n. 10, p. 1501-1510, 2006.
39. THE MTA COOPERATIVE GROUP. A 14-mongh randomized clinical trial of treatment strategies for Attention-Deficit/Hyperactivity Disorder. Archives of General Psychiatry, Chicago, v. 56, p. 1073-1086, 1999.
40. TURNER, D.; SAHAKIAN, B. Neuroethics of cognitive enhancement. Biosocieties, Cambridge, v. 1, n. 1, p. 113-123, 2006.
41. UN - UNITED NATIONS. Convention on Psychotropic Substances, 1971. Vienna, 1971. Disponível em: http://www.incb.org/pdf/e/conv/convention_1971_en.pdf. Acesso em: 2 mar. 2009.
42. WHITE, P. et al. Stimulant medication use, misuse, and abuse in an undergraduate and graduate. The Journal of American College Health, Linthicum, v. 54, n. 5, p. 261-268, 2006.
43. WOLPE, P. Treatment, enhancement, and the ethics of neurotherapeutics. Brain and Cognition, St. Catharines, v. 50, n. 3, p. 387-395, 2002.